Boehringer Ingelheim International Gmbh

Chitra Telang

Zeren Wang

Richard John Varsolona

Zhi-Hui Lu

Rolf-Stefan Brickl

Shirlynn Chen

Li Zhong

Danping Li

Mayur Suryakant Dudhedia

Siddharthya Mujumdar

Jihchin Chung

Described herein are solid oral dosage forms containing Compound (1) or a pharmaceutically acceptable salt thereof (Formula 1), wherein Compound (1) is in the amorphous state. Also described are solid oral dosage forms comprising a composition of Compound (1) in the amorphous state and one or more pharmaceutically acceptable excipients. Compound (1) is a specific inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. Thus, also described herein are methods for using the described solid oral dosage forms in the treatment of HCV infection. Also described are processes for the manufacture of the solid oral dosage forms. 

Solid oral dosage formulation of HCV inhibitor in the amorphous state

This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection: 

Solid state forms of a potent HCV inhibitor

Growing community of inventors

Brookfield, CT, United States of America

Chitra Telang